← All trials
NCT06737822
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2024
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2029
- First posted
- Dec 17, 2024
- Last posted
- Dec 17, 2024
- Enrollment
- 346
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- All India Institute of Medical SciencesLead sponsor
- All India Institute of Medical SciencesSponsor investigator
- King George's Medical UniversityCollaborator
- All India Institute of Medical SciencesCollaborator
- All India Institute of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.